Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour By Ogkologos - March 18, 2026 337 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANEUVER study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Tarlatamab Demonstrates Sustained Clinical Benefit and Potential Findings of Intracranial Activity... September 10, 2024 EMA Recommends Granting a Conditional Marketing Authorisation for Epcoritamab August 17, 2023 Droplet Transmission vs. Airborne… What’s the difference? August 10, 2020 UN Pandemic Declaration Reflects Key ESMO Priorities October 14, 2026 Load more HOT NEWS An Oncology Hospital at Home Model of Acute Care Shows Promise It’s a fair COP: Why our chief clinician went to a... ΟΓΚΟΙ ΕΓΚΕΦΑΛΟΥ TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer
